Unknown

Dataset Information

0

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents.


ABSTRACT:

Background

The aim of this study was to evaluate the effects of darbepoetin alfa (DA) on hemoglobin (Hb) concentration and the need for transfusions in multiple myeloma (MM) patients receiving chemotherapy with novel agents.

Methods

Of 251 patients with MM who received DA therapy for at least 4 weeks, 142 who did not receive RBC transfusion during 4 weeks after DA initiation and started DA therapy at baseline Hb <10.0 g/dL were analyzed.

Results

After 4 weeks of DA therapy, 80 (60.6%) of 132 patients with evaluable data had Hb that increased ?1.0 g/dL from baseline, while 50 (37.9%) had Hb that increased ?2.0 g/dL from baseline. Pretreatment Hb level did not correlate with the proportion of patients with increased Hb. The median duration of DA therapy was 9.0 weeks. At the end of DA therapy, of 135 patients with evaluable data, 86 (60.6%) had Hb that increased ?1.0 g/dL from baseline, while 67 (47.2%) had Hb that increased ?2.0 g/dL from baseline. Stage III disease according to the International Staging System and absence of myeloma bone disease at diagnosis were independent predictors of higher Hb response during early DA therapy.

Conclusion

We demonstrated the efficacy of DA therapy in a homogeneous group of MM patients receiving chemotherapy. DA therapy significantly increased Hb concentration, regardless of baseline Hb level.

SUBMITTER: Lee SE 

PROVIDER: S-EPMC6021573 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents.

Lee Sung-Eun SE   Jeon Young-Woo YW   Yoon Jae-Ho JH   Cho Byung-Sik BS   Eom Ki-Seong KS   Kim Yoo-Jin YJ   Kim Hee-Je HJ   Lee Seok S   Cho Seok-Goo SG   Kim Dong-Wook DW   Lee Jong Wook JW   Min Woo-Sung WS   Min Chang-Ki CK  

Blood research 20180625 2


<h4>Background</h4>The aim of this study was to evaluate the effects of darbepoetin alfa (DA) on hemoglobin (Hb) concentration and the need for transfusions in multiple myeloma (MM) patients receiving chemotherapy with novel agents.<h4>Methods</h4>Of 251 patients with MM who received DA therapy for at least 4 weeks, 142 who did not receive RBC transfusion during 4 weeks after DA initiation and started DA therapy at baseline Hb <10.0 g/dL were analyzed.<h4>Results</h4>After 4 weeks of DA therapy,  ...[more]

Similar Datasets

| S-EPMC6589825 | biostudies-literature
| S-EPMC8477647 | biostudies-literature
| S-EPMC8615675 | biostudies-literature
| S-EPMC3133722 | biostudies-literature
| S-EPMC5527057 | biostudies-literature
| S-EPMC4114494 | biostudies-literature
| S-EPMC3228121 | biostudies-other
| S-EPMC2988026 | biostudies-literature
| S-EPMC8338551 | biostudies-literature
| S-EPMC8202573 | biostudies-literature